Intermittent Hypoxemia, Lung Function Decline, Morbidity, and Mortality in COPD (PROSA Study). - Trial NCT06265623
Access comprehensive clinical trial information for NCT06265623 through Pure Global AI's free database. This phase not specified trial is sponsored by Universitätsklinikum Hamburg-Eppendorf and is currently Not yet recruiting. The study focuses on Chronic Obstructive Pulmonary Disease (COPD). Target enrollment is 148 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
No active intervention, but observational follow-up
Observational
other
Sponsor & Location
Universitätsklinikum Hamburg-Eppendorf
Timeline & Enrollment
N/A
Mar 01, 2024
Sep 30, 2029
Primary Outcome
Difference in FEV1(% of LLN) between baseline and end-of-follow-up
Summary
This study aims to analyze if patients with chronic obstructive lung disease who experience a
 decline of blood oxygen saturation during physical exercise have a disease course different
 from that of COPD patients who do not experience a decline in blood oxygen saturation during
 exercise. Patients will be followed for a total of 3 years.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06265623
Non-Device Trial